Metrika članka

  • citati u SCindeksu: [3]
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:0
  • preuzimanja u poslednjih 30 dana:0
članak: 10 od 13  
Back povratak na rezultate
Vojnosanitetski pregled
2001, vol. 58, br. 1, str. 65-72
jezik rada: srpski
vrsta rada: pregledni članak
objavljeno: 26/08/2019
Inhibitori trombocitnog glikoproteina IIb/IIIa u kardiologiji
aVojnomedicinska akademija, Klinika za urgentnu internu medicinu, Beograd
bVojnomedicinska akademija, Klinika za neurologiju, Beograd
cVojnomedicinska akademija, Institut za radiologiju, Beograd

Sažetak

Članak ne sadrži sažetak.

Ključne reči

koronarna, bolest; miokard, ishemija; glikoproteini trombocita, GP Ilb/IIIa kompleks; andagregaciona sredstva

Reference

(PRISM-PLUS) Study Investigators (1998) Inhibition of the platelet glycoprotein Ilb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction: Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms. New Engl J Med, 338: : 1488-97
*** (1998) Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. Journal of the American College of Cardiology, 32(7): 2003-2010
Altieri, D.C., Edginton, T.S. (1988) A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the stational state of the receptor CD11b/CD18 (MAC-1). J Immunol, 141: 2656-60
Ammar, T., Scudder, L.E., Coller, B.S. (1997) In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation, 95(3): 614-617
Antman, E.M., Giugliano, R.P., Gibson, C.M., McCabe, C.H., Coussement, P., Kleiman, N.S., Vahanian, A., Adgey, A.A., Menown, I., Rupprecht, H.J., van der Wieken, R., Ducas, J., Scherer, J., Anderson, K., van de Werf, F., Braunwald, E. (1999) Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial: The TIMI 14 Investigators. Circulation, 99(21): 2720-32
Antman, E.M., Braunwald, E. (1997) Acute myocardial infarction. u: Braunwald E. i dr. [ur.] Heart disease: A textbook of cardiovascular medicine, Philadelphia, itd: W.B. Saunders, str. 1184-288, Monograph on CD-ROM
Brener, S.J., Barr, L.A., Burchenal, J.E., Katz, S., George, B.S., Jones, A.A., Cohen, E.D., Gainey, P.C., White, H.J., Cheek, H.B., Moses, J.W., Moliterno, D.J., Effron, M.B., Topol, E.J. (1998) Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction: ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation, 98(8): 734-41
Campbell, K.R., Cantor, W., Sketch, M., Ohman, E. M. (2000) Glycoprotein IIb/IIIa inhibitors: Therapeutic applications in acute ST-segment elevation myocardial infarction. American Heart Journal, 140(6): S115-S124
CAPTURE Investigators (1997) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet, 349(9063): 1429-35
Carr, M.E., Carr, S.E., Hantgan, R.R., Braaten, J. (1995) Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus. Thrombosis and Haemostasis, 74(03): 499-505
Coller, B.S. (1997) GPIIb/IIIa antagonists: Pathophisiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost, 78: 730-5
Cooler, B.S. (1999) Binding of abciximab to Alpha V beta 3 and activated Alpha M beta 2 receptors: With a review of platelet-leukocyte interactions. Thrombosis and Haemostasis, 82(08): 326-336
EPILOG Investigators (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med, 336(24): 1689-96
Ferguson, J.J. (1999) Meeting highlights: Highlights of the 48th scientific sessions of the American College of Cardiology. Circulation, 100: 570-575
Foster, R.H., Wiseman, L.R. (1998) Abciximab: An updated review of its use in ischaemic heart disease. Drugs, 56: 629-65
Goa, K.L., Noble, S. (1999) Eptifibatide: A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs, 57: 439-62
Goan, K.L., Noble, S. (1999) Eptifibatide: A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs, 57: 439-62
Hamm, C.W., Heeschen, C., Goldmann, B., Vahanian, A., Adgey, J., Miguel, C.M., Rutsch, W., Berger, J., Kootstra, J., Simoons, M.L. (1999) Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels: c7E3 Fab antiplatelet therapy in unstable refractory angina: (CAPTURE) study investigators. N Engl J Med, 340(21): 1623-9
Holmes, M.B., Sobel, B.E., Cannon, C.P., Schneider, D.J. (2000) Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy: Orbofibn in patients with unstable coronary syndromes: Thrombolysis in myocardial infarction. American Journal of Cardiology, 85(4): 491-493
IMPACT-P Investigators (1997) Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II: Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet, 349(9063): 1422-8
Konstantopoulos, K., Kamat, S.G., Schafer, A.I., Banez, E., Jordan, R., Kleiman, N.S., et al. (1995) Shear-induced platelet aggregation is inhibited by in vivo infusion of an antiglycoprotein Ilb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation, 91:1427-31
Lefkovits, J., Ivanhoe, R.J., Califf, R.M., Bergelson, B.A., Anderson, K.M., Stoner, G.L., Weisman, H.F., Topol, E.J. (1996) Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction: EPIC investigators. American Journal of Cardiology, 77(12): 1045-1051
Liem, T.K., Teel, R., Shukla, S., Silver, D. (1997) The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies. Journal of Vascular Surgery, 25(1): 124-130
Newby, L.K., Symphony Steering Committee (1999) Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMP. American Heart Journal, 138(2): 210-218
Ohman, E.M., Kleiman, N.S., Gacioch, G., Worley, S.J., Navetta, F.I., Talley, J.D., Anderson, H.V., Ellis, S.G., Cohen, M.D., Spriggs, D., Miller, M., Kereiakes, D., Yakubov, S., Kitt, M.M., Sigmon, K.N., Califf, R.M., Krucoff, M.W., Topol, E.J. (1997) Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial: IMPACT-AMI Investigators. Circulation, 95(4): 846-54
o'Neill W.W., Serruys, P., Knudtson, M., van Es, G.A., Vender, Z.C., Timmis, G.C., et al. (2000) Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization: EXCITE trial investigators: Evaluation of oral xemilofiban in controlling thrombotic events. New Engl J Med, 342: 1316-1340
PRISM Investigators (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina: Platelet receptor inhibition in ischemic syndrome management: (PRISM) Study Investigators. N Engl J Med, 338(21): 1498-505
Simon, D.I., Xu, H., Ortlepp, S., Rogers, C., Rao, N.K. (1997) 7E3 Monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 17(3): 528-535
The Epistent Investigators (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet, 352(9122): 87-92
The Paragon Investigators (1998) International, randomized, controlled trial of Lamifiban (a platelet glycoprotein II/b/IIIa inhibitor), Heparin, or both in unstable angina: Platelet Ilb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Net. Circulation, 97: : 2386-95
The Pursuit Trial Investigators (1998) Inhibition of platelet glycoprotein Ilb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: Platelet glycoprotein Ilb/IIIa in unstable angina: Receptor supression using integrelin therapy. N Eng J Med, 339: 436-43
The Restore Investigators (1997) Effects of platelet glycoprotein IIb/IIIa Blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: Randomized efficacy study of tirofiban for outcomes and reste. Circulation, 96(5): 1445-1453
Topol, E., de Werf, W.F.J. (1998) Acute myocardial infarction and management. u: Topol E and Nissen S [ur.] Cardiovascular medicine, Philadelphia: Lippincott Raven, Monograph on CD-ROM, p. 425-66
Topol, E.J., Califf, R.M., Weisman, H.F., Ellis, S.G., Tcheng, J.E., Worley, S., Ivanhoe, R., George, B.S., Fintel, D., Weston, M. (1994) Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months: The EPIC Investigators. Lancet, 343(8902): 881-6
Topol, E.J., Ferguson, J.J., Weisman, H.F., Tcheng, J.E., Ellis, S.G., Kleiman, N.S. (1997) Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention: Epic investigator group: Evaluation of platelet IIb/IIIa inhibition for prevention of ischemic compli. JAMA: The Journal of the American Medical Association, 278(6): 479-484
Topol, E.J., Byzova, T.V., Plow, E.F. (1999) Platelet GPIIb-IIIa blockers. Lancet, 353(9148): 227-231
Tsao, P.W., Forsythe, M.S., Mousa, S.A. (1997) Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin αIIbß3 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Thrombosis Research, 88(2): 137-146
White, H.D. (1998) Unstable angina: Ischemic syndromes. u: Topol E, Nissen S [ur.] Cardiovascular medicine, Philadelphia: Lippincott - Raven, 395-424, Monograph on CD-ROM